Mice treated withSTING agonist only had a significantly longer median OS of 65 days compared to thevehicle-treated mice in which the median OS was 56 days (Fig. 1b, p = 0.0004).Significantly decreased ascites volumes and lower tumour burden was observed inthe STING agonist-treated mice (average 0.68 mL) compared to vehicle-treated mice(average 6.5 mL, Fig. 1c). This evidence concerns the gene STING1 and neoplasm.